Barclays
INKT icon

Barclays’s MiNK Therapeutics INKT Stock Holding History

Barclays’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$281 Buy
+24
New +$280 ﹤0.01% 5071
2026
Q1 		– Sell
-4
Closed -$45 – 5233
2025
Q4 		$45 Buy
+4
New +$52 ﹤0.01% 5134
2022
Q2 		– Sell
-33
Closed -$1K – 5142
2022
Q1 		$1K Buy
+33
New +$991 ﹤0.01% 4840

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Barclays's INKT Position: Q2 2026 in Review

Barclays opened a new position in MiNK Therapeutics (INKT) in Q2 2026: 24 shares worth $281. The stake represents ﹤0.01% of the portfolio and ranks #5071 among its holdings. This is a return to the name: Barclays previously reported a position in INKT as recently as Q4 2025.

Barclays first reported a position in INKT in Q1 2022 and has held it in 3 quarters since. The position peaked at $1K in Q1 2022. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Barclays held 24 shares of MiNK Therapeutics worth $281 as of Q2 2026.
  • MiNK Therapeutics was a new Barclays position in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5071 holding.
  • Barclays first reported a position in MiNK Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • Barclays's MiNK Therapeutics position peaked at $1K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.